Ibogaine
Ibogaine Treatment
A comprehensive, evidence-led resource on ibogaine: pharmacology, the research base, cardiac risk, candidacy, preparation and integration.
Ibogaine safety
Ibogaine safety, stated without softening.
Ibogaine is not risk-free. Its documented harms are specific, largely cardiac, and concentrated in people with pre-existing disease, electrolyte disturbance, interacting medication or no medical supervision. This page sets out what the systematic reviews and peer-reviewed literature record, and what screening can realistically achieve.
- Written by
- Johnny Tabaie
- Founder, Holistic Sanctuary
- Medically reviewed by
- Holistic Sanctuary Medical Team
- Attending physician and nursing leadership
- Published
- September 3, 2026
- Last reviewed
- September 3, 2026
Position
What the safety literature establishes.
Two findings recur across reviews of ibogaine. The first is that a meaningful number of people report substantial reductions in opioid withdrawal and craving after supervised administration. The second is that ibogaine has been associated with serious medical complications and with deaths. A 2022 systematic review of 24 clinical studies including 705 participants reported both, and concluded that the compound warrants rigorous medically supervised research rather than uncontrolled adoption.
Forensic and toxicological reviews of fatalities associated with ibogaine consistently identify contributing factors: pre-existing cardiovascular disease, concurrent substance use, interacting medication, and absence of medical monitoring. That pattern is the strongest argument for structured screening. It is not an argument that screening makes the procedure safe, and we do not make that argument.
We do not use the phrases "perfect safety record", "100% safe" or "foolproof" about ibogaine or about anything else offered here. They are not descriptions of medicine.
Risk map
The specific risks, one at a time.
- 01
hERG blockade and QT prolongation
Ibogaine and noribogaine inhibit the hERG potassium channel that governs cardiac repolarisation. The result is lengthening of the QT interval, demonstrated in laboratory work and observed clinically. Because noribogaine has a long half-life, the effect can outlast the subjective experience.
- 02
Ventricular arrhythmia
Prolonged QT predisposes to torsades de pointes and other ventricular arrhythmias. Bradycardia is also commonly described. Forensic reviews of ibogaine-associated deaths identify cardiac mechanisms as the most frequent proximate cause.
- 03
Cardiac screening
A baseline 12-lead ECG with QTc measurement is the minimum standard. Abnormal or equivocal findings trigger specialist review and may end the process. Screening identifies risk; it does not make the intervention safe.
- 04
Drug interactions
Additive QT prolongation is a central concern: certain antipsychotics, some antidepressants, several macrolide antibiotics and azole antifungals, ondansetron and methadone among others. A complete list of prescriptions, over-the-counter drugs and supplements is required.
- 05
CYP2D6 variability
Ibogaine is metabolised principally by CYP2D6. Genetic poor metabolisers, and people taking CYP2D6 inhibitors including several SSRIs, can reach far higher exposure than expected. This is one plausible explanation for reactions that appear idiosyncratic.
- 01
Electrolytes
Hypokalaemia and hypomagnesaemia independently increase arrhythmia risk and are common after prolonged substance use, poor nutrition or vomiting. Correction beforehand is standard, and uncorrected disturbance is a reason to postpone.
- 02
Medical comorbidities
Hepatic and renal impairment alter metabolism and clearance. Significant cardiovascular, respiratory or metabolic disease raises baseline risk. Baseline testing is obtained, but testing cannot turn a high-risk person into a low-risk one.
- 03
Neurological effects
Ataxia, tremor, nausea, vomiting and prolonged unsteadiness are frequently reported and raise fall and aspiration risk during recovery. High-dose rodent studies demonstrated cerebellar Purkinje cell damage; human relevance remains debated.
- 04
Psychiatric considerations
The experience is long and strongly autobiographical. Psychotic and bipolar spectrum illness, current suicidality and recent psychiatric crisis require specialist evaluation and may exclude a person entirely.
- 05
Polysubstance exposure
Concurrent stimulants, alcohol, benzodiazepines and opioids complicate cardiac risk and withdrawal management simultaneously. Accurate disclosure changes clinical decisions more than almost anything else a person can do.
Screening
What screening can and cannot do.
What it can do
Screening identifies prolonged QTc before rather than after exposure, corrects electrolyte abnormalities, surfaces interacting medication, establishes hepatic and renal function, and identifies psychiatric contraindications. It also identifies people for whom the answer is simply no — which is the most valuable thing it produces.
What it cannot do
It cannot predict individual pharmacokinetics with precision, cannot exclude idiosyncratic reactions, and cannot make an inherently risky intervention safe. Residual risk remains after every reasonable precaution, and informed consent has to say so in writing.
Medication is a prescriber's decision
Nothing here is a reason to stop prescribed medication. Opioid agonist therapy in particular should never be discontinued abruptly or independently: loss of tolerance raises overdose risk substantially. Any adjustment is planned in advance with the prescribing clinician.
Where this sits
Safety is inseparable from the preparation process described on the preparation page, and from the broader evidence review on the ibogaine treatment guide. For how to evaluate a provider's safety standards, see ibogaine treatment centers.
Medical supervision
Why supervision matters more than any single test.
Serious adverse events during ibogaine exposure can evolve rapidly. A prolonged QT interval can become an arrhythmia within minutes. Vomiting and altered consciousness create aspiration risk. Sudden changes in blood pressure and heart rate are common. These events require immediate clinical recognition, resuscitation equipment, and the capacity to transfer to emergency care if needed.
That is why medical supervision is not an add-on. It is the condition under which the existing evidence base becomes ethically defensible. A setting without continuous monitoring, cardiac-capable staff, and emergency protocols cannot claim to have addressed the risks described in the literature, regardless of how thorough its intake questionnaire may be.
Questions
Frequently asked questions
- What is the main safety concern with ibogaine?
- The principal documented risk is cardiac: ibogaine and its metabolite noribogaine block hERG potassium channels and can prolong the QT interval on an ECG, predisposing some people to dangerous ventricular arrhythmias such as torsades de pointes.
- Can screening make ibogaine safe?
- No. Screening can identify and remove several known risk factors — prolonged QTc, electrolyte disturbance, interacting medication, significant organ disease — but it cannot eliminate all risk. Residual risk remains even after thorough screening.
- Why do electrolytes matter so much?
- Low potassium and magnesium independently increase arrhythmia risk and are common after prolonged substance use, vomiting, diarrhoea or poor nutrition. Correcting them before administration is a standard part of cardiac risk reduction.
- Which medications interact dangerously with ibogaine?
- Drugs that further prolong the QT interval or inhibit CYP2D6 metabolism are the biggest concerns. These include certain antidepressants, antipsychotics, macrolide antibiotics, azole antifungals, some antiemetics, and methadone. A full medication and supplement review is essential.
- Does ibogaine affect the brain or nervous system?
- Acute neurological effects such as ataxia, tremor, nausea, vomiting and prolonged unsteadiness are commonly reported. Animal studies at high doses have raised concerns about cerebellar toxicity, but the direct relevance to humans under clinical conditions remains debated and uncertain.
- Can people with psychiatric conditions take ibogaine?
- Not always. Psychotic disorders, bipolar illness, current suicidality and recent psychiatric crisis require specialist evaluation and may be contraindications. The experience is long and autobiographical, which can destabilise vulnerable individuals.
- Why is medical supervision described as essential?
- Because serious adverse events can occur suddenly and require immediate intervention. Continuous monitoring, resuscitation capability, and clinician presence are the minimum conditions under which the existing risk profile becomes defensible.
- Is ibogaine ever safe to use alone or at home?
- No. Unsupervised use is strongly represented in the fatality literature. This site provides no dosing or self-administration guidance for that reason.
Sources
References
- 01Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules (2015). Source
- 02Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci (2012). Source
- 03Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (2016). Source
- 04Köck P et al. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat (2022). Source
- 05Glue P et al. Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin Pharmacol Drug Dev (2016). Source
- 06Nielsen LM et al. The cardiac effects of ibogaine: a systematic review of the literature. Psychopharmacology (2024). Source
- 07National Institute on Drug Abuse — Medications to treat opioid use disorder. Source
Explore
Continue reading
Ibogaine treatment
The full resource: research, opioid dependence, preparation, integration and comparison.
Read moreIbogaine preparation
The screening sequence in detail, from medication review to ECG and consent.
Read moreIbogaine treatment centers
How to evaluate a provider's medical, safety and integration standards.
Read moreRelated
Related reading
Ibogaine
Ibogaine Preparation
Medical, psychological and practical preparation: history, medication review, ECG, laboratory assessment, consent and integration planning.
Ibogaine
Best Ibogaine Treatment Centers
A consumer guide to evaluating an ibogaine provider: screening, cardiac assessment, medical oversight, emergency preparedness and transparency.
Ibogaine
Ibogaine Integration
Why the weeks after an experience matter: reflection, behavior, sleep, nutrition, relationships, meaning and ongoing professional support.
Insights
Latest Insights
Browse all insights
Benzodiazepine Treatment
Benzodiazepine Detox
Benzo detox and withdrawal treatment: a physician-directed taper, twenty-four hour monitoring, nine hours of daily therapy and the in-house Brain Repair IV protocol.
Ibogaine
Best Ibogaine Treatment Centers
A consumer guide to evaluating an ibogaine provider: screening, cardiac assessment, medical oversight, emergency preparedness and transparency.
Benzodiazepine Treatment
Holistic Benzodiazepine Treatment
Physician-supervised benzodiazepine detox and withdrawal support: gradual tapering, nine hours of daily one-to-one therapy, the in-house Brain Repair IV protocol, and whole-body restoration in a private oceanfront setting.
Mental Health
Holistic Mental Health Treatment
An integrative approach to PTSD, trauma, depression and anxiety that treats sleep, nutrition, environment and behavior as clinical variables.
Holistic Treatment
Holistic Rehab
Rehabilitation as system repair: mental health, behavior, environment, nutrition and sleep, with specialized medical support where it is needed.
Ibogaine
Ibogaine Integration
Why the weeks after an experience matter: reflection, behavior, sleep, nutrition, relationships, meaning and ongoing professional support.
Ibogaine
Ibogaine Preparation
Medical, psychological and practical preparation: history, medication review, ECG, laboratory assessment, consent and integration planning.
Ibogaine
Ibogaine Treatment
A comprehensive, evidence-led resource on ibogaine: pharmacology, the research base, cardiac risk, candidacy, preparation and integration.
Speak with our admissions team.
Admissions is a confidential clinical conversation, not a sales call. We review history, current medication, and goals before anyone is accepted.